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Abstract: Melatonin exhibits extraordinary diversity in terms of its functions and distribution.
When discovered, it was thought to be uniquely of pineal gland origin. Subsequently, melatonin
synthesis was identified in a variety of organs and recently it was shown to be produced in the
mitochondria. Since mitochondria exist in every cell, with a few exceptions, it means that every
vertebrate, invertebrate, and plant cell produces melatonin. The mitochondrial synthesis of melatonin is
not photoperiod-dependent, but it may be inducible under conditions of stress. Mitochondria-produced
melatonin is not released into the systemic circulation, but rather is used primarily in its cell of origin.
Melatonin’s functions in the mitochondria are highly diverse, not unlike those of sirtuin 3 (SIRT3).
SIRT3 is an NAD+-dependent deacetylase which regulates, among many functions, the redox state
of the mitochondria. Recent data proves that melatonin and SIRT3 post-translationally collaborate in
regulating free radical generation and removal from mitochondria. Since melatonin and SIRT3 have
cohabitated in the mitochondria for many eons, we predict that these molecules interact in many other
ways to control mitochondrial physiology. It is predicted that these mutual functions will be intensely
investigated in the next decade and importantly, we assume that the findings will have significant
applications for preventing/delaying some age-related diseases and aging itself.
Keywords: reactive oxygen species; oxidative stress; molecular pathways; sirtuins; antioxidant
enzymes; oxidative phosphorylation
1. Introduction
Genetic diversity often exceeds that which is predicted based on the number of genes that have
been sequenced [1,2]. This suggests that epigenetic processes may account for the greater molecular
heterogeneity than that which is apparent in organisms [3,4]. Within recent decades, unraveling the
mechanisms whereby the large variety of epigenetic modifications (post-translational modifications)
are achieved has been a major area of research [5–7].
Sirtuins are a class of histone deacetylates that are homologues of a translational repressor, the first
of which was originally discovered in yeast (Saccharomyces cerevisiae) and named mating-type regulator
1 (MAR1) [8,9]. Almost a decade later, Rine and colleagues [10] extended the findings of Klar et al. [8,9]
Int. J. Mol. Sci. 2018, 19, 2439; doi:10.3390/ijms19082439 www.mdpi.com/journal/ijms
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when they identified four deacetylases in S. cerevisiae; they abandoned the name mating-type regulator
and renamed the enzymes silent information regulators; since they had identified four such enzymes
they were named SIR1-4.
In the last 25 years, the associated enzymes, now called sirtuins (SIRT), have been major agents
of intensive investigative endeavor and they have been linked to a wide variety of physiological
processes [11–13]. The actions include longevity-promoting effects [14,15], for their ability to inhibit
cancer [16,17] and, more recently, because of their involvement in circadian rhythm regulation [18–20].
The sirtuin family in mammalian cells now includes seven members (SIRT1–7); they are
collectively known as the cellular acylome [21]. Each sirtuin has a well-conserved NAD+-binding
domain. The sirtuins have a variety of enzymatic activities and functions and they are differentially
distributed at the subcellular level (Figure 1) [1,22]. One major function of sirtuins is to act as
sensors of energy availability and, during each reaction, they consume molecules of NAD+ [5,23].
The best-known members of the sirtuin family that function as metabolic sensors include SIRT1, which
is primarily located in the nucleus of cells and SIRT3 which is concentrated in the mitochondria [24,25].
Mitochondrial SIRT3 [12,26] is susceptible to regulation by exogenously-supplied melatonin; this is
consistent with melatonin being a mitochondria-targeted antioxidant [27–30].
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Figure 1. This figure identifies the primary location of sirtuins 1–7 in eukaryotes. Sirtuins are NAD+-
dependent deacetylates which account for post-translational modifications of molecules within cells; 
sirtuins have a wide variety of functions including the promotion of longevity and the prevention in 
age-related diseases. For the purposes of the current report, specific interest is directed to 
mitochondrial SIRT3, the activity of which has been shown to be modulated by melatonin. SIRT3 is 
primarily located in the mitochondria where it co-localizes with melatonin. Both these molecules are 
involved in redox regulation and, as shown in this report, they are functionally intertwined. Single 
arrowheads identify structure; double headed arrows identify movement of molecules. 
Figure 1. This figure identifies the primary location of sirtuins 1–7 in eukaryotes. Sirtuins are
NAD+-dependent deacetylates which account for post-translational modifications of molecules
within cells; sirtuins have a wide variety of functions including the promotion of longevity and the
prevention in age-related diseases. For the purposes of the current report, specific interest is directed to
mitochondrial SIRT3, the activity of which has been shown to be modulated by melatonin. SIRT3 is
primarily located in the mitochondria where it co-localizes with melatonin. Both these molecules are
involved in redox regulation and, as shown in this report, they are functionally intertwined. Single
arrowheads identify structure; double headed arrows identify movement of molecules.
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Of the seven sirtuins, three (SIRT3, SIRT4 and SIRT5) are located, although not exclusively, in the
mitochondria, attesting to their potential involvement in their regulation of metabolism and especially
of respiratory changes and oxidative phosphorylation [31–33]. Evidence has accumulated showing
that melatonin, which exists in mitochondria along with SIRT3, influences the deacetylation of this
sirtuin [28]. Since SIRT3 is known to modulate the redox state of the mitochondria, as does melatonin,
we surmised these actions may be interrelated. Those relationships are discussed in this report.
2. Melatonin: Harnessing Free Radicals
The discovery of melatonin as a free radical scavenger 25 years ago [34] was preceded by reports
that the indole protected against DNA damage as a result of being exposed to a chemical carcinogen [35]
and was alleged to be a life-promoting molecule, as was SIRT3. Given that both these processes were
believed to be related to oxidative stress [36,37], the initial studies designed to test the radical trapping
ability of melatonin were undertaken. The hydroxyl radical (•OH), the most destructive of the
oxygen-based toxic species, was generated by exposing a solution of hydrogen peroxide (H2O2) to
ultraviolet light. A spin trapping agent, 5,5′-dimethylpyrroline N-oxide (DMPO), was added to the
solution with or without the addition of melatonin; DMPO captures the •OH with the formation of
an adduct, DMPO-•OH [38]. In the absence of melatonin in the solution, this adduct was abundant;
however, when melatonin was added to the solution adduct formation was almost zero indicating
melatonin had scavenged the •OH and reduced their availability to form a DMPO-•OH. When
melatonin was compared to two other known •OH scavengers, glutathione or mannitol, melatonin
proved superior as a radical quencher in this pure chemical system. The presence of the DMPO-•OH
adduct was verified using high performance liquid chromatography with an electrochemical detector
(HPLC-EC) and further confirmed with electron spin resonance spectroscopy (ESR) [39]. Given that
these studies were performed using a cell-free system, it was obvious that the radical scavenging
actions did not require membrane melatonin receptors (or any other receptor/binding site) which had
been described [40,41] to exist in many cells.
The discovery that melatonin was a highly-efficient •OH scavenger was met with considerable
skepticism by mainstream free radical biologists. They were resistant for several reasons. The first
reason seemed to be was that they simply did not believe the data. Previously, there had been no hint
that melatonin or related molecules had radical scavenging potential. Also, they argued that because
of its very high reactivity, the •OH interacts (is scavenged by) with any molecule in its vicinity. In our
study, however, we had compared melatonin with two confirmed •OH scavengers, i.e., glutathione
and mannitol, both of which showed less reactivity to the free radical than did melatonin. Within
a year after the initial publication, the radical scavenging capability of melatonin was confirmed in
another chemical system using other methods [42].
Another reason that was used for rejecting the idea of the radical scavenging capability of
melatonin was that there was little evidence that it functions in the detoxification and the reduction
of oxidative stress in vivo or in cultured cells. This deficiency was soon rectified, however, since
within two years melatonin was documented to reduce oxidative stress in vivo due to glutathione
depletion [43], ionizing radiation exposure [44], paraquat toxicity [45], lipopolysaccharide [46,47],
kainic acid [48], and ischemic/reperfusion injury [49]. The cellular damage in each of these situations
is known to involve toxic free radicals and strongly support the idea that melatonin can protect a
variety of molecules against oxidative stress in vivo.
The repeated independent verification of the capability of melatonin to function as a free
radical scavenger [50–68] and to hold oxidative stress in check has solidified the idea that this
intrinsically-produced indole is a legitimate in vivo agent that limits oxidative damage. An additional
small percentage of the total number of published reports substantiating the ability of melatonin to
limit oxidative stress under conditions that would have otherwise had disastrous consequences are
summarized in Table 1 [69–100].
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Table 1. Experimental evidence that melatonin reduces oxidative stress and related events in cells,
animals, and humans. Listed here are representative publications where melatonin was used to
diminish oxidative damage and/or associated physiological/molecular changes following exposure to
a variety of different chemical toxins/processes that normally lead to oxidative mutilation of critical
molecules, cellular apoptosis, and compromised organ function. As mentioned, these are representative
reports; there are many more. If the reader has a specific interest in a toxin/melatonin interaction,
it (they) could be easily found in an appropriate literature search. Also, for many of the subjects
listed, there are numerous publications documenting the protective function of melatonin, e.g., in
ischemia/reperfusion injury, heavy metal toxicity, etc. The reports are in chronological order.
Toxin/Process Tissue Protected Reference
Carbon tetrachloride Liver [69]
Hyperbaric oxygen Lung and brain [70]
2-Nitropropane Lipid and DNA [71]
Cerulein Pancreas [72]
Quinolinic acid Brain [73]
δ-Aminolevulinic acid Lipid and DNA [74]
Neonatal asphyxia (human) Lipid [75]
Ochratoxin A Liver and kidney [76]
Ultraviolet radiation Leucocytes [77]
Respiratory distress syndrome (human) Lung [78]
1-Methyl-4-phenyl-1,2,3,6-tetrahydro pyridine Brain [79]
Organ transplantation Liver [80]
Diquat Lipid [81]
Cerebral hypoperfusion Brain [82]
Aspirin (human) Gastrointestinal tract [83]
Opisthorchis viverrini (liver fluke) Liver [84]
Methamphetamine Brain [85]
Doxorubicin Heart [86]
Cobra toxin Multiple tissues [87]
Strenuous exercise Skeletal muscle [88]
Ionizing radiation Oral mucosa [89]
Ischemia/reperfusion Heart [90]
Cadmium Brain [91]
Phosphine Heart [92]
Neonatal sepsis (human) Neonate [93]
ST-segment elevation, myocardial infarction (human) Heart [94]
Ischemia/reperfusion Brain [95]
p-Cresol Mesenchymal stem cells [96]
Arsenic trioxide Liver [97]
Type 2 diabetes Cardiovascular system [98]
Hexavalent chromium Spermatogonia [99]
Ischemia/reperfusion Lung [100]
Some of the mechanisms by which melatonin detoxifies the peroxyl radical include (a) single
electron transfer; (b) hydrogen atom transfer; or (c) possibly radical adduct formation [101–103]
(Figure 2). When melatonin interacts with other radicals the adducts formed may be different than the
one shown in the figure. Despite overwhelming evidence, there may be some who deny that melatonin
is a radical scavenger or that it can curb oxidative stress [104,105] or they claim that it is only a weak
scavenger [104,106].
Those who assert that melatonin is unlikely an essential physiological antioxidant in vivo argue
that, because pharmacological quantities must be given to combat severe oxidative damage, e.g., during
ischemia/reperfusion events, it is normally inconsequential as an inhibitor of oxidative stress.
Oxidative damage would never occur if physiological concentrations of all antioxidants combined,
i.e., vitamin C, glutathione, uric acid, melatonin, etc., were adequate to overcome the massive onslaught
of free radicals that occur under such conditions. Thus, “pharmacological” amounts of free radicals
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are produced during these catastrophic events, which requires pharmacological concentrations of any
antioxidant, not only melatonin, to effectively combat the molecular damage.
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Figure 2. The means by which melatonin detoxifies a lipid peroxyl radical (LOO•) are shown in this
figure and include electron transfer, hydrogen ion transfer and radical adduct formation. These are
examples of actions of melatonin that are receptor independent. If the free radical was a •OH radical
rather than a LOO• radical, because of the very high reactivity of the former, the number of reaction
products would be much greater.
Other aspects of melatonin that contribute to its image as a highly-effective antioxidant include
(a) metabolites that are formed when melatonin incapacitates a radical species also function in free
radical detoxification [66,107–113] in what is called the antioxidant cascade; (b) melatonin chelates
metal ions that are involved in the Haber-Weiss and Fenton reactions thereby preventing the formation
of the devastatingly reactive •OH [114,115]; (c) melatonin stimulates antioxidant enzymes which
removes potential damaging species from the intercellular environment [116–123] while; (d) inhibiting
pro-oxidant enzy es (e.g., myeloperoxidase, lipoxygenase, etc.) [124]; (e) melatonin also synergizes
with classic rad cal scaveng rs making them mo e eff ive in reducing oxidative d mage [125,126];
(f) melatonin stimulates a cytosolic detoxifying enzyme quinone reductase [ 27]; and (g) melatonin
increases the efficiency of the transfer of electrons between the mitochondrial respiratory complexes
thereby reducing electron leakage and free radical formation [128,129]. Considering the multiple
means by which melatonin annihilates reactive oxygen species, it would seem to be relentless in
preventing molecular damage and maintaining a functional subcellular infrastructure.
3. Intrinsic Sources of Melatoni
Melatonin, although initially thought to be synthesized only in the pineal gland [130–132],
was soon found to be produced in the vertebrate retinas as well [133,134]. Of these two sites,
only the mamm l an pineal gla is known to release significant amounts, presumably by simple
diffusion out of the cells, f melatonin that would functi n systematically, with two routes of discharge
being utilized, i.e., directly into the third ventricle of the central nervous system [124,135–137] and
into the blood capillaries that are abundant in this tissue [138,139]. Although there may be some
“incidental” leakage of small amounts of melatonin into the blood from other tissues (e.g., gut) there is
no compelling evidence for a persistent or cyclic release of melatonin from these organs [140] as has
been shown for the pineal gland [141,142]. If melatonin escapes the pinealocyte by simple diffusion
into the blood, why melatonin produced in other cells does not do so as well is unexplained. Thus,
following surgical removal of the pineal gland, circulating levels of melatonin persist at values that
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are barely measurable [141,142]. Exogenously administered melatonin, e.g., orally, subcutaneously,
or intraperitoneally, does cause transient large increases in blood melatonin concentrations [143,144].
3.1. Melatonin in Bodily Fluids
Despite these general observations, based on the high melatonin concentrations in some bodily
fluids, the possibility that other cells may produce and release melatonin into fluids other than the
blood has been speculated, e.g., very high levels of melatonin in the bile (Figure 3) may be from
hepatocytes [145] and concentrations of melatonin in ovarian follicular fluid that exceed those in the
blood may be from granulosa cells [146,147] and perhaps from oocytes themselves [148].
Int  J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 27 
 
the blood, why melatonin produced in other cells does not do so as well is unexplained. Thus, 
fol owing gical removal of the pineal gland, circula ing levels of melatonin persist at val es that 
are barely measurable [141,142]. Exogenously administered melatonin, e.g., orally, subcutaneously, 
or intraperitoneally, does cause transient large increases in blood melatonin concentrations [143,144]. 
3.1. Melatonin in Bodily Fluids 
Despite these general observations, based on the high melatonin concentrations in some bodily 
fluids, the possibility that other cells may produce and release melatonin into fluids other than the 
blood has been speculated, e.g., very high levels of melatonin in the bile (Figure 3) may be from 
hepatocytes [145] and concentrations of melatonin in ovarian follicular fluid that exceed those in the 
blood may be from granulosa cells [146,147] and perhaps from oocytes themselves [148]. 
 
Figure 3. Radioimmunoassayable melatonin levels in the bile of six mammalian species. These values 
are clearly much higher than in the blood, both during the day or at night (two bars on far left). Levels 
of melatonin in the fluids other than the blood that exceed the concentration of this indole in the blood 
is not unusual. Melatonin values in several other bodily fluids and within subcellular organelles also 
exceed those in the blood. 
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nucleus (SCN) [151–153], and on peripheral oscillators that exist in presumably all cells [154–157]. How 
important the quantity of melatonin released from the pineal gland is relative to the total amount of 
oxidative stress an animal experiences, e.g., as a result of the persistent mitochondrial metabolism of 
oxygen and production of adenosine triphosphate (ATP), is not well defined [158–160]. Moreover, 
whether the elevated oxidative stress that occurs after surgical removal of the pineal gland is exclusively 
related to the loss of the nocturnal rise in melatonin or whether it is a consequence of circadian 
dysregulation remains undetermined. Any treatment that causes a perturbation of the melatonin 
rhythm is likewise associated with some change in circadian rhythmicity, and vice versa [161]. Thus, 
identifying which of those is the cause of a specific abnormality cannot always be deciphered.  
If the amount of melatonin that is released from the pineal gland is, in fact, relevant as a direct 
intracellular free radical scavenger in peripheral tissues, by necessity it would have to enter cells and 
gain access to mitochondria, the major site of reactive oxygen species (ROS) generation. Physiological 
levels of circulating melatonin have a short half-life in the blood (30–40 min) indicating it is rapidly 
taken up by peripheral tissues, either for metabolic breakdown (e.g., by hepatocytes) or by all tissues 
so it can carry out its intracellular functions (e.g., as a radical quencher). 
Under extremely stressful conditions, e.g., forced swimming for rats, even high nocturnal levels 
of melatonin in the blood almost instantaneously disappear [162,163]; this very rapid disappearance 
Figure 3. Radioimmunoassayable melatonin levels in the bile of six mammalian species. These values
are clearly much higher than in the blood, both during the day or at night (two bars on far left). Levels
of melatonin in the fluids other than the blood that exceed the concentration of this indole in the blood
is not unusual. Melatonin values in several other bodily fluids and within subcellular organelles also
exceed those in the blood.
In the pineal gland, melatonin is produced and released in a photoperiodic-dependent circadian
manner [149,150] with the cerebrospinal fluid (CSF) and blood levels modulating, respectively,
organismal-wide circadian rhythms via actions on the master biological clock, the suprachiasmatic
nucleus (SCN) [151–153], and on peripheral oscillators that exist in presumably all cells [154–157]. How
important the quantity of melatonin released from the pineal gland is relative to the total amount of
oxidativ stress an animal experiences, e.g., as r sult of th persistent mitocho rial metabolism
of oxygen and producti n of adenosine triphosphate (ATP), is not well defi ed [158–160]. Moreover,
whether the elevated oxidative stress that occurs after surgical remov l of the pineal gland is exclusively
related to the loss of the nocturnal rise in melatonin or whether it is a consequence of circadian
dysregulation remains undetermined. Any treatment that causes a perturbation of the melatonin
rhythm is likewise associated with some change in circadian rhythmicity, and vice versa [161]. Thus,
identifying which of those is the cause of a specific abnormality cannot always be deciphered.
If the amount of melatonin that is released from the pineal gland is, in fact, relevant as a direct
intracellular free radical scavenger in peripheral tissues, by necessity it would have to enter cells and
gain access to mitochondria, th m jor site of r active oxygen sp cies (ROS) generation. Physiological
levels of circulating latonin have a short half-life in the blood (30–40 mi ) indicating it is rapidly
taken up by peripheral tissues, either for metabolic breakdown (e.g., by hepatocytes) or by all tissues
so it can carry out its intracellular functions (e.g., as a radical quencher).
Under extremely stressful conditions, e.g., forced swimming for rats, even high nocturnal levels
of melatonin in the blood almost instantaneously disappear [162,163]; this very rapid disappearance
seemingly exceeds the ability of the liver to catabolize such large amounts of melatonin in very
Int. J. Mol. Sci. 2018, 19, 2439 7 of 28
short time. Rather, the swift drop in circulating blood melatonin concentrations under conditions of
intensive stress more likely relates to its rapid uptake by cells throughout the body where it is needed
to neutralize, directly or indirectly, the massive numbers of free radicals that are being produced,
especially at the mitochondrial level [164,165].
3.2. Mitochondrial Melatonin
That melatonin can enter cells and their mitochondria is undisputed. Using fluorescence imaging
techniques, Jou and her colleagues [166–168] have repeatedly shown that high free radical generation
by mitochondria is quickly quenched when the cells are incubated in a solution containing melatonin
(Figure 4). These findings are consistent with melatonin from the incubation medium quickly
penetrating the membranes of both the cell and of the mitochondria where it neutralizes, either
by direct scavenging or via indirect means, the free radicals formed in the intermembrane space and in
the matrix. Besides functioning as a radical scavenger in mitochondria, melatonin has other actions
that probably necessitate its presence in these organelles. Thus, at this level, melatonin enhances
mitochondrial antioxidant enzymes, promotes respiration and ATP production, negates the intrinsic
apoptosis pathway, and mediates its effects on sirtuins [1,169,170]. These actions would generally
require more time to appear since they would involve induction mechanisms.
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Figure 4. Fluorescent imaging of the intense generation of reactive oxygen species in a cultured
astrocyte at 5 min (C) and 10 min (D) after its exposure to an oxidizing agent (H2O2). The cell shown
in panels (E) (5 min) and (F) (10 min) was also exposed to the H2O2, but additionally, melatonin was
present in the culture medium. Clearly, melatonin was taken into the cell and into mitochondria where
it reduced r active oxygen species generation r q ickly scavenged them when they were pro uced.
Dihydrorh dam ne 123 was used to visualize fr e radical g neration. (A) is an en a ced pseudocolor
image w ich shows the hig r levels of reactive oxyg n sp cies in mit chondria relative to other
organelles. (B) is the astrocyte (also shown in the panels (C,D)) before its exposure to H2O2. Figure
provided by Mei-Jie Jou. Scale bar = 1 µm.
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To explain the ever-widening array of cells that synthesized melatonin, we recently proposed that
multicellular organisms actually synthesize melatonin in their mitochondria [171]. This hypothesis
is based on considerations related to the proposed origin of mitochondria in eukaryotes. According
to the Endosymbiotic Theory, mitochondria in eukaryotes are derived from bacteria which were
initially engulfed for their nutrient value; eventually, the phagocytosed bacteria developed a symbiotic
relationship with their host cells and evolved into mitochondria (Figure 5) [172,173]. During evolution,
the newly-developed mitochondria kept the important functions that their precursors possessed. Thus,
they retained their ability to carry on oxidative phosphorylation and ATP production and their capacity
to synthesize melatonin [28,171]. While bacteria have long been known to produce ATP as an energy
source, only recently have bacteria been shown to contain melatonin, presumably a result of synthesis
in these organisms [174–176]. Thus, any cell (animal or plant) that contains mitochondria may also have
the capability to produce melatonin [28,171] since mitochondria derived from melatonin-producing
bacteria [174,175]. The production of melatonin by mitochondria is now supported by reports that
have been published after mitochondria being a source of melatonin was suggested (see below).
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Figure 5. A summary of the major theory, the Endosymbiotic Theory, that explains the evolution of
mitochondria as they exist in current-day eukaryotic cells. Accordingly, prokaryotic “cells” evolved
features of eukaryotes over millions of years. An example of one major development, as it relates to
the current review, is the phagocytosis of proteobacteria by prokaryotes; the bacteria were initially
engulfed as nutrients by their digestion in intracellular granules. Eventually, the engulfed bacteria
established a mutually beneficial association (a symbiotic relationship) with the host cell; the new
endosymbiont sent much of its genetic material to the nucleus of the host while the symbiont gradually
evolved into a mitochondrion. Since the proteobacteria already had the capability to produce energy
(ATP) and melatonin, these functions were retained by the mitochondria and proved beneficial to the
host cells. As a result, it is our contention that every mitochondria-containing cell produces melatonin
in their mitochondria. The Endosymbiotic Theory for the origin of mitochondria was suggested more
than 100 years ago and has been refined, and widely accepted, in the last three decades. Using current
molecular technologies, it has been possible to document many metabolic similarities between bacteria
and mitochondria. The Endosymbiotic Theory is used as an explanation as to why mitochondria
produce melatonin, a function inherited from their precursors, i.e., bacteria.
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In 2012, Venegas and coworkers [177] collected the brain and liver from rats at 4-h intervals
over a 24-h light:dark cycle. For the purposes of determining whether melatonin was differentially
distributed in neurons and hepatocytes and, if so, whether the concentrations varied between the light
and dark periods, they isolated cellular membranes, cytosol, mitochondria, and nuclei. The results
unequivocally show that, at least for brain cells and hepatocytes, melatonin levels are not in equilibrium
at the subcellular level. Of the four fractions in which melatonin was measured, brain mitochondria
had much higher melatonin concentrations than the other sites; thus, the levels of melatonin were about
25 times greater in mitochondria than in cytosol (Figure 6). When hepatocyte-derived mitochondria
were examined, these values were not at the same high level as those seen in brain mitochondria.
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Figure 6. Concentrations and fluctuations of melatonin in organelles obtained from cells of the cerebral
cortex of rats that were either intact (SPx) or pinealectomized (Px). Only in cellular membranes did
Px markedly change melatonin levels; in this organelle, melatonin values rose substantially as a
consequence of pineal removal (p < 0.001). In the mitochondria and nucleus, at one time point each,
melatonin levels were elevated (** p < 0.05 and *** p < 0.001 respectively). Tissues were collected at 4 h
intervals over a 24-h light:dark cycle. The period of darkness is identified by the horizontal black bar.
What is most apparent is that levels of melatonin in brain mitochondria greatly exceed its values in
other subcellular locations. Figure provided by Dario Acuna-Castroviejo.
The intracellular melatonin levels were clearly not derived from the blood since when these
measurements were made in cells that were obtained from pinealectomized animals, a procedure
which reduces circulating melatonin levels to essentially zero, the concentrations of melatonin actually
increased in the membranes (10-fold) and cytosol (2-fold), but was essentially without influence on
these levels in either the brain nuclei or mitochondria [177]. In both the intact and pinealectomized
animals, organellar levels of melatonin did not vary over a 24-h period. The exceptionally high levels of
melatonin in brain mitochondria speaks to the likelihood that this organelle is uncommonly efficient in
sequestering/retaining melatonin or it produces it. The remarkably high concentrations of melatonin
in brain mitochondria is fortuitous considering that this organelle produces many free radicals during
respiration. This is supported by the fact that the central nervous system has a very high metabolic
rate and uses a much larger portion of the inhaled oxygen than would be predicted based on its size.
Int. J. Mol. Sci. 2018, 19, 2439 10 of 28
The observations of Venegas et al. [177] do not preclude the possibility that mitochondria may both
avidly take up melatonin from extracellular locations, e.g., blood, as well as synthesize it. As shown
above, the reports of Jou et al. [167,168] document that when cultured cells are incubated with
melatonin, it may rapidly gain access to mitochondria where it visually lowers free radical products.
Similarly, also as mentioned above, melatonin given to animals via any route reduces reactive oxygen
species damage to cells implying that the indole gets to the source of the bulk of the free radicals,
i.e., the mitochondria.
It has generally been assumed that, as noted above, due to the high lipophilicity of melatonin,
it readily enters cells via simple diffusion. While this remains a possible route for its entrance into cells,
recent studies have examined active transport means by which it passes through membranes. The first
serious attempt to determine how high intracellular levels of melatonin are achieved, Hevia et al. [178]
examined the uptake of melatonin in a variety of normal and cancer cells. For this purpose, cells were
incubated in a solution containing pharmacological concentrations (1 mM) of melatonin. Independent
of the cell type, incubation for 24 h always increased intracellular levels of the indole. The findings
were not consistent with the passive uptake of the indole; rather the data suggested a protein-mediated
uptake process which was impacted by the ambient glucose concentration. The protein involved was
subsequently identified as the GLUT1 transporter. Accelerated melatonin uptake is further exaggerated
in a high glucose environment in erythrocytes [179].
Huo and colleagues [180] recently defined another means by which melatonin may enter both
cells and mitochondria; in this case, however, only human cancer cells were examined. The results are
consistent with the involvement of the PEPT1/2 oligopeptide transporters in the transfer of melatonin
through both the cell and mitochondrial membranes. Docking analysis studies as well as kinetic
measurements support a role for the oligopeptide transporters aiding the uptake and retention of
melatonin within cells and especially within mitochondria. For a detailed discussion of the active
transport mechanisms for melatonin, the reader is directed to a recent report by Mayo et al. [1].
In view of the seemingly special association of melatonin with mitochondria [27,171] along with
the protective advantages against free radicals that this would provide, interest in the potential local
synthesis of melatonin by mitochondria has become a subject of active investigation. Considering
that melatonin-producing bacteria [174,175] are widely accepted to be the progenitors of eukaryotic
mitochondria (see Endosymbiotic Theory mentioned above and in Figure 5), it seems likely that this
important function would have been retained by eukaryotic cells as we have proposed [171].
3.3. Mitochondrial Synthesis of Melatonin
In addition to the rapid uptake of melatonin by mitochondria, as noted above, we have recently
drawn attention to the unique relationship of melatonin with mitochondria [27] and we proposed that
this organelle likely produces its own melatonin [171]. Despite this, some toxic radicals escape being
neutralized and damage adjacent macromolecules. The idea that mitochondria synthesize melatonin
is based primarily on the predicted origin of mitochondria from bacteria, there is one very early
study that also alluded to this possibility. In 1975, Kerenyi et al. [181] while examining the subcellular
distribution of the rate-limiting enzyme in melatonin synthesis, arylalkylamine N-acetyltransferase
(AANAT), claimed that in pinealocytes the reaction product for this enzyme is exclusively limited to the
mitochondria. While the images of the mitochondria in this ultrastructural study are rather fragmented,
nevertheless, the author’s interpretation of the findings cannot be disputed; the reaction product is
in mitochondria. The results of the Kerenyi et al. [181] study were, however, rarely acknowledged in
the subsequent years since individuals working on the synthesis of melatonin were likely convinced
that this process was relegated to the cytosol and, also, the cytochemical method used to identify
AANAT activity was less than optimal. The findings reported in the Kerenyi et al. [181] report were,
however, used to support the argument of Tan et al. [171] that mitochondria are the primary site of the
conversion of serotonin to melatonin.
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He et al. [148] recently examined mouse oocytes as a likely location of melatonin synthesis. In an
electron micrographic study, immunocytochemical AANAT was restricted to the mitochondria. More
importantly, when they incubated isolated oocyte mitochondria with serotonin, a necessary precursor
of melatonin production, melatonin levels were markedly increased in the mitochondria as well as
in the medium in which they were incubated; in the absence of serotonin no melatonin was formed.
These findings have implications beyond the identification of melatonin in oocyte mitochondria. In all
offspring of fertilized ova, the mitochondria are exclusively of maternal origin. Thus, it seems likely
that since oocyte mitochondria produce melatonin, all cells in the offspring would also do so.
A more complete study to establish where in cells melatonin formation occurs was published
by Suofu and colleagues [182]. They used non-synaptosomal brain mitochondria for this purpose.
The two terminal enzymes in melatonin production, AANAT and HIOMT, along with the AANAT
chaperone, 14-3-3ζ, were in mitochondria. Like Venegas et al. [177], when melatonin synthesis was
measured over a 24-h light:dark cycle, no rhythm in any of the parameters was apparent. Digesting the
outer mitochondrial membrane with a combination of proteins K and digitonin did not lead to a loss
of enzyme activities prompting the authors to conclude that melatonin synthesis likely occurs in the
matrix. Finally, when brain mitochondria were incubated with deuterated (D4) serotonin, they yielded
D4-N-acetylserotonin and D4 melatonin. The findings of Suofu et al. [182] are the most complete data
indicating that mitochondria are a location of melatonin synthesis.
While the findings of Venegas et al. [177] and Suofu and coworkers [182] are noteworthy, in both
reports the organ of greatest concern was the brain. In this organ, melatonin concentrations in
mitochondria were very high [177] and the proteins of the melatonin-forming enzymes, AANAT
and HIOMT/ASMT, were also present [182]. Thus, the presumed production of melatonin in neural
tissue, of which the pineal is a part, may be unique to this organ and awaits identification in other
tissues. However, based on the findings of He et al. [148] on the production of melatonin by oocyte
mitochondria along with the organism-wide distribution of mitochondria from the oocyte, we feel that
the mitochondria of all cells manufacture melatonin, possibly in tissue specific amounts as needed,
i.e., melatonin may be inducible.
Melatonin solicits a large variety of auxiliary means to reduce mitochondrial damage potentially
inflicted on hapless macromolecules as a consequence of the persistent low-level free radical generation
or, in the case of toxin exposure, hypoxia, etc., to the torrents of ROS that are produced. Some of
the allied processes utilized by melatonin to reduce these catastrophic effects, e.g., indiscriminate
molecular destruction which ultimately leads to cellular apoptosis, include improving the efficacy of
the mitochondria respiratory complexes [129,183,184], enriching ATP production [185,186], reducing
free radical generation by limiting electron leakage, commonly referred to as radical avoidance [128],
upregulating antioxidative enzymes [187,188], stimulating glutathione synthesis [189,190], direct
radical detoxification [103,191] and probably yet to be defined means. The outcome of these combined
actions is the preservation of cellular and organ physiology, as well as the prevention of organismal
death, by mitigating cellular loss due to apoptosis [167,192–195].
4. The Melatonin/SIRT3 Interactions
Many post-translational modifications are mediated by sirtuins [6,7]. SIRT3 is a member of a
family of seven sirtuins (1–7) that are collectively referred to as the cellular acylome [21]. Sirtuins
mediate post-translational modifications of lysine residues; these actions are reversible and involve
proteins in a wide variety of molecular pathways. As such, the sirtuins have a major impact on the
physiology of cells [21,196–200]. Like melatonin, SIRT3 has actions related to reducing oxidative stress.
For example, both melatonin and SIRT3 influence the generation of partially reduced oxygen species
at the level of the mitochondrial respiratory complexes and both detoxify these reactants by promoting
antioxidant enzyme activities [122,123]. Forkhead box 03 (FOXO3a) is a direct target of SIRT3 which
is also involved in processes related to defense against oxidative damage [201,202], not unlike the
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actions of melatonin. Considering the common functional features of melatonin, FOXO3a and SIRT3
in mitochondria, their physiological association would seem to be a logical assumption.
4.1. Reproductive Organ Protection
Considering that human females are planning pregnancies later in their reproductive life span,
there is increasing interest in identifying molecules that maintain ovarian, oocyte and uterine
physiology in a more youthful state to ensure a successful pregnancy and healthy offspring. The human
female reproductive axis typically declines quickly in women after the age of 35. Since, as in other
organs, free radical damage contributes to diminished reproductive processes including the onset
of menopause [203,204], the antioxidant melatonin has been tested for its potential in deferring the
slowed follicular maturation and reduced oocyte quality observed in the aging female. The results of
these studies verify that melatonin has significant benefits in maintaining the function of the ovary
and adnexa which normally deteriorates with age or after exposure to toxins, etc. [205–209].
Obesity in rodents, as in humans, due to feeding/consuming a high fat diet (HFD) causes the
acetylation of SIRT3, which reduces its activity and causes the catastrophic cellular damage due
to unrestrained ROS generation. This damage occurs in many tissues including the oocyte, which,
because of its diminished quality, jeopardizes successful fertilization and pregnancy. Because of the
worldwide increase in obesity, female fertility has shown a marked decline. Since mitochondrial
SIRT3 is suppressed in obese rodents, which leads to reduced SOD2 and unrestrained ROS formation,
Han et al. [210] fed melatonin to obese rats. As anticipated, melatonin greatly improved oocyte quality
and fertilizability; this was accompanied by an activation (deacetylation) of SIRT3, which induced
SOD2 ultimately reducing oxidative stress in the oocytes. To further confirm the mechanism by
which melatonin improved oocyte quality in obese mice, we used morpholino to knockdown SIRT3,
a procedure that eliminated the protective actions of melatonin at the oocyte level (Figure 7).
When melatonin was orally administered chronically to aging female mice and rats, clearly their
reproductive function and performance were improved relative to those in age-matched controls not
treated with melatonin. In mice, the improvement was obvious in the maintained follicle pool, litter
size after mating and telomere length as well as oocyte number and quality [211]. Similarly, in female
rats, melatonin delayed ovarian aging as estimated by many of the same parameters [212] measured
in mice. Both Song et al. [211] and Tamura and coworkers [212] predicted that SIRT3 upregulation
would be related to the melatonin maintenance of ovarian physiology in the aged rodents. In mice,
melatonin treatment was accompanied by enhanced ovarian granulosa cell SIRT3 activity along with
the translocation of FOXO3a to the nucleus where it bound to the promoters of SOD2 and catalase
(CAT) [211]. Both SOD2 and CAT are mitochondrial antioxidant enzymes. The mitochondria of the
granulosa cells also less easily generated ROS due to the H2O2 treatment when melatonin was present.
In addition to the upregulation of sirtuins, melatonin may defer ovarian aging due to its direct radical
scavenging activities, stimulation of telomerase, reducing autophagy, etc.
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(A) and mean spindle/chromosomal defects (B) of the oocytes (values are means ± SEM). Obesity
was associated with an increase in ROS and elevated molecular damage in oocytes. Melatonin (MEL)
treatment reduced both parameters. When SIRT3 was silenced (with siRNA) the actions of melatonin
were negated. This suggests that the antioxidant action of melaton n in oocyt s depen s on stimulation
(deacetylati n) of SIRT3 which enhances the activity of the antioxidant enzyme, superoxide dismutase.
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The data showing that melatonin reduces free radical generation/damage in mitochondria along
with the findings of several groups which indicate that this organelle rapidly takes up and synthesizes
melatonin is of great interest; however, the specific mechanisms by which the indole limits oxidative
damage to this organelle remains to be determined. As already noted, melatonin has a plethora of
means to curtail molecular damage resulting from exposure to free radicals. Which accounts for the
reduced oxidative stress along with the subcellular mechanisms involved requires definition.
4.2. Cardiovascular Protection
There are numerous published reports showing that melatonin reduces ischemia/reperfusion
(I/R) injury in multiple organs [213–215] (see also some data in Table 1). One I/R model involving
the heart was used to examine the possible involvement of mitochondrial SIRT3 upregulation in
melatonin’s protective actions in myocardial tissue subjected to anoxia/reoxygenation. Yu and
colleagues [216] tested this in type 1 diabetic rats (induced by streptozotocin) after left anterior
descending coronary artery ligation for 30 min. This study was specifically directed to examining
the action of melato in a the mitochondrial lev l. This comprehensive investigation validated
that melato in in I/R-d maged myocardium improved cardia physiology by augmenting ATP
production and improving respiratory chain function (Complexes II, III, and IV), stimulating SOD2
activity, limiting apoptosis of cardiomyocytes and reducing H2O2 generation and lipid peroxidation.
Mechanistically, Yu et al. [216] found that melatonin’s beneficial effects stemmed from its stimulation of
the adenosine monophosphate–activated kinase (AMPK)-PGC-1α-SIRT3 signaling and the activation
of mitochondrial superoxide dismutase (SOD) and elevated NRF (nuclear factor (erythroid-derived
2)-like 2) and TFAM (mitochondrial transcription factor A) expression (Figure 8).
Tw subsequent reports also confirmed the involvement of melatonin a d SIRT3 in protecting the
heart from ROS injury [217,218]. Based on the findings of Zhai et al. [217], the role played by SIRT3
was shown by th observation that a selective inhibitor of SIRT3 [3-(1H-1,2,3-triazol-4-yl) pyridine,
3-TYP) negated the effects of melatonin as a cardioprotective agent. Due to the depression of SIRT3,
SOD2 is not upregulated and oxidative stress remains at a high level which severely compromises
melatonin’s ability to protect the myocardium from free radical destruction.
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Figure 8. A summary of the proposed mechanisms by which melatonin preserves myocardial cell
function after ischemia/reperfusion injury in type 1 diabetic rats. The involvement of AMPK→pAMPK
was shown using compound C, a specific blocker of AMPK-signaling. The role of SIRT3 was
documented with the use of SIRT3 siRNA. Melatonin protects against myocardial damage due to
ischemia/reperfusion as indicated. Figure drawn from the findings of Yu et al. [216]. Red arrows
indicate stimulation; blue arrows indicate inhibition; green arrows indicate flow of information.
Zhang et al. [218] used a different model to judge how effective melatonin is in protecting the
myocardium from free radical damage. The model was the diabetic cardiomyopathic mouse. Heart
function was monitored echocardiographically; these measurements showed that melatonin mitigated
left ventricular cardiac remodeling and preserved cardiac function in diabetic animals. The authors
suspected melatonin’s advantage resulted from its actions at the mitochondrial level. To prove this,
Zhang et al. [218] examined the involvement of SIRT3; this confirmed that melatonin inhibited Mst
phosphorylation which led to SIRT3 stimulation and elevated antioxidant protection. Melatonin’s
efficacy disappeared in Mst knockout mice. They concluded that, as others have, that the upregulation
of SIRT3 is essential to the ability of melatonin to protect mitochondria from oxidation stress.
Endothelial cell dysfunction in coronary arteries and elsewhere is a feature that is essential for
the development of atherosclerotic lesions [219]. While the basic process involves inflammation of
the endothelial lining, the associated oxidative stress including oxidation of low-density lipoprotein
are important mediators of endothelial cell malfunctions eventually culminating in plaque formation
and other subsequent negative effects [220]. Previously, melatonin was shown to maintain the
optimal fluidity of cell membranes [221,222] and to protect them from damage normally inflicted by
free radicals.
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Against this background of information, Lee et al. [223] examined the efficacy of melatonin to
forestall endothelial cell damage in an ischemic limb, after lipopolysaccharide treatment and in an
in vitro model using human umbilical vein endothelial cells (HUVECs). As anticipated, melatonin
protected against endothelial cell destruction in the in vivo model and reduced oxidative stress levels,
inflammatory reactions, cell death and mitochondrial dysfunction in HUVECs. Of special interest to
the current report, when mitochondrial SIRT3 was silenced (with siRNA), melatonin’s in vitro effects
were absent indicating that, as in other reports, melatonin’s antioxidant actions in mitochondria rely,
to a large degree, on SIRT3 deacetylation. The authors point out that the reversal of the actions of
melatonin by silencing SIRT3 are as others have observed in earlier reports. They do not provide,
however, any additional information as to the signaling mechanisms by which melatonin modulates
SIRT3/oxidative stress/mitochondrial malfunction.
4.3. Hepatic Protection
Fluorosis is a condition that occurs as a consequence of the long-term ingestion of fluoride.
It is a progressive degenerative condition which is, in part, a result of exaggerated ROS production
in hepatocyte mitochondria [224]. Melatonin has been successfully used to combat liver damage
related to chronic ingestion of fluoride by experimental animals [225]. The mechanisms of protection
afforded by melatonin involve limiting oxidative stress. Song et al. [226] showed that incubating
human liver cells (L02) with sodium fluoride (NaF) increased intracellular superoxide production
leading to the accumulation of oxidative stress and apoptotic cell death; these changes were attenuated
when melatonin was added to the incubation medium. At the molecular level, melatonin stimulated
SIRT3 deacetylation leading to the rapid dismutation of the superoxide; this was accompanied by
SIRT3-triggered DNA binding of FOXO3a. The inhibitory pathway analysis showed that melatonin
enhanced PGe-1α expression due to the activation of PI3K/AKT signaling. With the use of membrane
melatonin receptor blocker, these workers proved the effects of melatonin were mediated by the
MT1 receptor; this was confirmed when the L02 cells were transfected with MT1 siRNA. Presumably,
the MT1 receptor involved was in the plasma membrane although it may have been in the outer
mitochondrial membrane [182].
Chen and coworkers [227] examined the association of melatonin and SIRT3 on oxidative damage
induced in cultured L02 hepatocytes and in mice after ligation of the bile duct. L02 is a spontaneously
immortalized cell line. For the cell culture study, the active biliary toxin was glycochenodeoxycholic
acid (GCDCA). Co-treatment of hepatocytes with melatonin and GCDCA highly significantly reduced
mitochondrial ROS generation that was apparent in cells only treated with GCDCA. The protective
actions of melatonin were associated with an upregulation of SIRT3 and the elevated deacetylation of
SOD2. The actions of melatonin were blocked in hepatocytes transfected with AMP-activated, alpha-1
catalytic subunit (AMPK) siRNA. In the in vivo studies where the bile duct was ligated to produce
cholestasis, the findings were similar. Melatonin’s beneficial actions in these studies were most likely
related to its ability to modulate the AMPK-SIRT3-SOD2 pathway. The in vivo results are consistent
with the ability of melatonin to reduce gross liver pathophysiology resulting from cholestasis due to
obstruction of the bile duct [228,229].
5. Concluding Remarks
In recent years, investigations related to melatonin’s actions in cells have become progressively
more focused to the mitochondria without, however, precluding functions in other subcellular
compartments. Since melatonin is a powerful inhibitor of oxidative stress, its actions at the level
of the mitochondria may not only be fortuitous, but necessary considering its highly protective actions.
Mitochondria, more than any other organelle, spawns ROS/free radicals even under so-called “resting”
conditions, but especially under taxing circumstances. It is essential that potentially-damaging ROS be
quelled at their source to ensure the molecular damage they mete out can be averted.
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More than a decade ago, it was immunocytochemically shown that melatonin quenched the
fluorescent-signal associated with ROS generation in the mitochondria [167]. Roughly a decade later,
melatonin was shown to be in exceptionally high concentrations in mitochondria, more so than in any
other cellular compartment [177]. Among several interesting features of the Venegas et al. [177] report
was that the mitochondria, in which the very high levels of melatonin were measured, were obtained
from brain tissue, rather than being of pineal gland origin. After consideration of the preceding
data, we speculated that melatonin is likely produced in the mitochondria of all cells, animals, and
plants [171]. This hypothesis relies heavily on what is referred to as the Endosymbiotic Theory (Figure 5)
for the origin of mitochondria in eukaryote cells. Since bacteria contain melatonin, presumably a
result of its synthesis in these prokaryotes [174], and mitochondria derived from bacteria that were
initially phagocytized as food by early eukaryotes, we surmised that the melatonin-synthesizing
machinery of bacteria was retained by the evolved mitochondria. This idea stimulated investigations
that have led to compelling evidence that mitochondria of every cell fabricates melatonin for its own
use [145,182]; this explains the very wide distribution of melatonin in multicellular organisms [230,231].
That mitochondria produce melatonin has only been shown in a small number of cells, i.e., brain and
oocyte. Whether this is a universal feature of mitochondria awaits investigation.
The original studies by Jou et al. [167,168] also suggested that, in addition to manufacturing
melatonin, it is rapidly taken up by cells from the extracellular environment. This entry was thought
to be related to simple diffusion of melatonin, which is highly lipophilic, through the plasma and
mitochondrial membranes. While this possibility is still viable, melatonin has been shown to enter
cells via the GLUT1 transporter [178] and by means of the PEPT1/2 oligopeptide transporters [180].
The latter proteins also exist in mitochondrial membranes where they presumably aid in the rapid
uptake of melatonin against a gradient. It is anticipated that data related to the uptake and synthesis
of melatonin by mitochondria will grow rapidly in the next five years.
Like melatonin, sirtuins are both ubiquitously distributed and likely acquired by eukaryotes after
the engulfment of α-proteobacteria [232]. As with melatonin, the sirtuins are therefore very ancient.
The fact that both melatonin and sirtuins co-existed in cells for eons, it could be expected that they
would have “learned” to collaborate. The data summarized above clearly shows that SIRT3 is required
for melatonin to neutralize oxidative stress at the mitochondrial level, at least in the conditions under
which it was investigated. These findings, although not numerous, were comprehensively reviewed
within the last year [1,28]. The fact that melatonin promotes the deacetylation of mitochondrial SIRT3
and FOXO3a, which results in the stimulation of the antioxidant enzyme, SOD2, leaves unexplained the
importance of the direct free radical scavenging component of melatonin in protecting this organelle
and the cell as a whole from free radical damage; this issue requires resolution.
SIRT3 has multiple functions in mitochondria. It impacts the respiratory chain complexes and elevates
ATP production, influences enzymes of the citric acid cycle, holds sway over amino acid metabolism
and controls fatty acid oxidation. Additionally, SIRT3 affects mitochondrial dynamics [233–237].
Melatonin shares many of these same actions [231,238–243]. Whether melatonin’s effects on mitophagy,
mitochondrial bioenergetics, fusion or fission are a consequence of its epigenetic actions may be a fruitful
area of investigation.
Considering the multiple overlapping functions and their very long-standing cohabitation in
mitochondria, it seems likely that SIRT3 and melatonin have interactions beyond regulating SOD2
activity. It is our prediction that they cooperate in the regulation of a variety of mitochondrial functions.
We also expect these interactions will be clarified in the near future.
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